Paul W.H.I. Parren, PhD

Executive Vice President and Head of R&D at Lava Therapeutics

Paul_Parren_Lava_therapeutics_lumc_Biotech_Pharma_summit_2021_profile_gallery

Title: Bispecific γδ-T cell engagers for the treatment of cancer

  • Next generation bispecific antibody technology for T cell engagement
  • Widening the therapeutic window
  • Progress of LAVA's lead program towards the clinic